Summit Therapeutics Inc. (SMMT)
Largest Insider Buys in Sector
SMMT Stock Price History Chart
SMMT Stock Performance
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae …
Insider Activity of Summit Therapeutics Inc.
Over the last 12 months, insiders at Summit Therapeutics Inc. have bought $786,094 and sold $0 worth of Summit Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Summit Therapeutics Inc. have bought $125.54M and sold $321,463 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Dhingra Ankur (Chief Financial Officer) — $750,000. Zanganeh Mahkam (Chief Executive Officer) — $411,094.
The last purchase of 80,321 shares for transaction amount of $298,594 was made by Zanganeh Mahkam (Chief Executive Officer) on 2024‑03‑27.
List of Insider Buy and Sell Transactions, Summit Therapeutics Inc.
| 2024-03-27 | Chief Executive Officer | 80,321 0.0113% | $3.72 | $298,594 | +192.78% | |||
| 2024-03-26 | Chief Financial Officer | 100,000 0.0143% | $3.75 | $375,000 | +191.98% | |||
| 2024-03-26 | Chief Executive Officer | 30,000 0.0043% | $3.75 | $112,500 | +191.98% | |||
| 2023-12-13 | Chief Financial Officer | 20,400 0.0027% | $2.17 | $44,254 | +106.38% | |||
| 2023-12-12 | Chief Executive Officer | 5,000 0.0007% | $2.07 | $10,350 | +118.72% | |||
| 2023-10-13 | Chief Operating Officer | 2.98M 0.4265% | $1.68 | $5M | +147.62% | |||
| 2023-03-08 | Co-CEO & President | 23.53M 4.2977% | $1.05 | $24.7M | +26.64% | |||
| 2023-03-07 | Chief Financial Officer | 196,362 0.0395% | $1.05 | $206,180 | +39.49% | |||
| 2023-03-06 | Chief Executive Officer | 376.49M 75.2052% | $1.05 | $395.31M | +38.49% | |||
| 2022-08-16 | Chief Executive Officer | 94.85M 61.3078% | $0.97 | $92M | +70.30% | |||
| 2022-08-16 | Co-CEO & President | 1.03M 0.6664% | $0.97 | $999,997 | +70.30% | |||
| 2022-08-16 | Chief Financial Officer | 37,685 0.0244% | $0.97 | $36,554 | +70.30% | |||
| 2021-05-12 | Chief Executive Officer | 11.37M 12.0109% | $5.24 | $59.56M | -6.40% | |||
| 2021-05-12 | Chief Operating Officer | 389,077 0.4112% | $5.24 | $2.04M | -6.40% | |||
| 2020-11-30 | Sale | Chief Scientific Officer | 13,713 0.0195% | $4.44 | $60,886 | +36.67% | ||
| 2020-11-27 | Sale | Chief Scientific Officer | 29,569 0.043% | $4.39 | $129,808 | +41.94% | ||
| 2020-11-25 | Sale | Chief Scientific Officer | 12,070 0.0175% | $4.32 | $52,142 | +43.93% | ||
| 2020-11-24 | Sale | Chief Scientific Officer | 11,374 0.0164% | $4.21 | $47,885 | +46.08% | ||
| 2020-11-23 | Sale | Chief Scientific Officer | 6,987 0.01% | $4.40 | $30,743 | +39.77% | ||
| 2020-11-06 | Chief Executive Officer | 14.07M 20.8007% | $3.34 | $47M | +89.54% |
Insider Historical Profitability
| Zanganeh Mahkam | Chief Executive Officer | 24923800 3.3814% | $19.00 | 6 | 0 | +30.18% |
| Dhingra Ankur | Chief Financial Officer | 354958 0.0482% | $19.00 | 4 | 0 | +54.89% |
| DUGGAN ROBERT W | Chief Executive Officer | 552354161 74.9366% | $19.00 | 4 | 0 | +47.98% |
| Soni Manmeet Singh | Chief Operating Officer | 2976190 0.4038% | $19.00 | 1 | 0 |
Institutional Investor Ownership
| BlackRock | $40.67M | 1.4 | 9.82M | +0.66% | +$264,786.11 | <0.01 | |
| State Street | $33.59M | 1.16 | 8.11M | +230.36% | +$23.42M | <0.01 | |
| Fidelity Investments | $33.01M | 1.14 | 7.97M | +85,445.28% | +$32.98M | <0.01 | |
| The Vanguard Group | $30.09M | 1.04 | 7.27M | +3.63% | +$1.05M | <0.01 | |
| Geode Capital Management | $13.05M | 0.45 | 3.15M | +2.16% | +$276,271.19 | <0.01 |